# A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

> **NCT04657224** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 75 (actual)

## Conditions studied

- Lymphoma, Non-Hodgkin
- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** JNJ-64264681
- **DRUG:** JNJ-67856633

## Key facts

- **NCT ID:** NCT04657224
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-25
- **Primary completion:** 2025-01-16
- **Final completion:** 2025-01-16
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2025-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04657224

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04657224, "A Study of JNJ-64264681 and JNJ-67856633 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04657224. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*